YKL ‐40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C by Fontana, Robert J. et al.
CL IN ICAL STUDIES
YKL-40 genetic polymorphisms and the risk of liver disease progression
in patients with advanced fibrosis due to chronic hepatitis C*
Robert J. Fontana1, Heather J. Litman2, Jules L. Dienstag3, Herbert L. Bonkovsky4, Grace Su1, Richard K. Sterling5,
Anna S. Lok1 for the HALT-C Trial Group
1 Department of Internal Medicine, University of Michigan Medical School MI, USA
2 New England Research Institutes MA, USA
3 Gastrointestinal Unit (Medical Services), Massachusetts General Hospital and the Department of Medicine, Harvard Medical School Boston, MA, USA
4 Departments of Medicine and Molecular and Structural Biology and the Liver-Biliary-Pancreatic Center, University of Connecticut Health Center CT,
USA
5 Hepatology Section, Virginia Commonwealth University Medical Center VA, USA
Keywords
cirrhosis – decompensation – genetic
polymorphisms – hepatitis C – interferon –
virological response
Abbreviations
ALT, alanine aminotransferase; AST,
aspartate aminotransferase; BMI, body mass
index; CHC, chronic hepatitis C; CTP, Child-
Turcotte-Pugh; HALT-C, Hepatitis C Antiviral
Long-Term Treatment against Cirrhosis Trial;
HCC, hepatocellular carcinoma; IL28B,
interleukin 28 B; INR, international
normalized ratio; PCR, polymerase chain
reaction; SNP, single nucleotide
polymorphism; SVR, sustained virological
response.
Correspondence
Robert J. Fontana, MD, Professor of Internal
Medicine, University of Michigan Medical
Center, Ann Arbor, MI 48109-0362, USA
Tel: (734) 936 4780
Fax: (734) 936 7392
e-mail: rfontana@med.umich.edu
Received 11 July 2011
Accepted 21 October 2011
DOI:10.1111/j.1478-3231.2011.02686.x
Abstract
Background/Aims: The aim of this study was to explore the association of a
functional YKL-40 promoter polymorphism (rs4950928) with baseline dis-
ease stage, response to antiviral therapy and risk of liver disease progression
in a group of patients with chronic hepatitis C (CHC). Methods: YKL-40
promoter polymorphisms were determined in 456 Hepatitis C Antiviral
Long-term Treatment against Cirrhosis (HALT-C) Trial patients with bridg-
ing fibrosis or cirrhosis entering a prerandomization lead-in peginterferon/
ribavirin 24-week treatment phase and in 462 patients followed for a mean
of 3.8 years after randomization to maintenance peginterferon or observa-
tion. Results: Mean patient age was 49.5 years, 70.4% were men and 71.2%
were Caucasian. The 17% frequency of the YKL-40 minor allele (T) was simi-
lar to that reported in the general population. YKL-40 genotype was associ-
ated significantly with baseline serum YKL-40 levels but was not associated
with the likelihood of a virological response following 24–48 weeks of pegin-
terferon/ribavirin therapy. Serum YKL-40 levels remained significantly lower
during follow-up in the randomized TT homozygotes compared with CT
heterozygotes and CC homozygotes (P < 0.001). Despite this association,
YKL-40 genotype was not associated with the risk of clinical or histological
liver disease progression. Conclusions: A reduced frequency of the protective
YKL-40 promoter polymorphism was not observed in the HALT-C Trial
patient population. The absence of an association between YKL-40 promoter
polymorphisms and baseline liver disease severity as well as with the risk of
liver disease progression over time suggests that this polymorphism is not
associated with disease progression in CHC patients with established fibrosis.
YKL-40 is a fibroblast growth factor that contributes to
the remodelling of inflamed tissues such as human liver
and synovia via the degradation of low-density extracel-
lular matrix (1–4). Secreted by activated macrophages,
YKL-40 is believed to act as a chemoattractant for endo-
thelial cells, can modulate angiogenesis during tissue
repair and is expressed in multiple tissues including
human liver (5, 6). The serum level of YKL-40 has been
evaluated as a noninvasive marker of various chronic
inflammatory and fibrotic liver diseases, including
alcoholic liver disease and chronic hepatitis C (CHC)
(1, 7, 8). The strong correlation between serum YKL-40
levels and hepatic mRNA levels in patients with CHC
suggests that serum YKL-40 levels, in part, reflect ongo-
ing hepatic fibrogenesis (1). In addition, among patients
with CHC, serial measurement of serum YKL-40 levels
can differentiate patients with slow from those with
rapid progression of liver fibrosis (1). Genetic polymor-
phisms in the CHI3L1 gene located on chromosome
*The HALT-C Trial was registered with clinicaltrials.gov
(#NCT00006164). This is publication #74 of the HALT-C Trial.
Liver International (2012)
© 2011 John Wiley & Sons A/S 665
Liver International ISSN 1478-3223
1q32.1 that encodes for YKL-40 were described recently
(9, 10). In particular, a functional upstream promoter
polymorphism of CHI3L1 (rs4950928) has been associ-
ated with reduced serum levels of YKL-40 in multiple
independent patient cohorts and with a reduced risk of
asthma and bronchial hyperresponsiveness (10). In
addition, the presence of this functional polymorphism
in a large cohort of German patients with CHC was
associated with a lower stage of liver fibrosis as well as
lower serum YKL-40 levels (11).
The Hepatitis C Antiviral Long-term Treatment
against Cirrhosis (HALT-C) Trial was a prospective
multicentre study of maintenance peginterferon in
patients with CHC and advanced fibrosis who failed to
respond to prior interferon-based treatment (12). Dur-
ing a 24-week lead-in phase, all patients were retreated
with full-dose peginterferon alfa-2a and ribavirin (13).
Patients with HCV RNA detectable at week 20 were cat-
egorized as nonresponders and were eligible for ran-
domization, whereas week-20 virologic responders
continued combination treatment for a full 48 weeks in
the ‘responder’ arm of the trial (Fig. 1). Recently, in 513
HALT-C Trial patients participating in an ancillary
study of serum fibrosis markers, we demonstrated that
serum YKL-40 levels were associated strongly with the
stage of hepatic fibrosis (14). In addition, lower baseline
serum YKL-40 levels were associated independently with
a higher likelihood of achieving a week-20 virological
response during the lead-in phase (15). Furthermore,
serum YKL-40 levels during treatment helped distin-
guish patients who went on to achieve a sustained viro-
logical response (SVR) from those who experienced
virologic breakthrough or relapse. Finally, a multivariate
model that included baseline serum YKL-40 levels was
the best predictor of clinical outcomes in 462 patients
followed for a median of 3.8 years in the randomized
phase of the HALT-C Trial (16).
The aim of this study was to determine the relation-
ship between YKL-40 promoter polymorphisms at
rs4950928 and baseline serum YKL-40 levels in the
HALT-C Trial patients who were enrolled in the serum
fibrosis marker ancillary study. Anticipating that the
YKL-40 promoter polymorphism T minor allele would
be associated with lower serum YKL-40 levels, we also
sought to determine whether this genetic polymorphism
was associated with the likelihood of a virological
response during the lead-in phase of this study. Finally,
we evaluated the relationship between YKL-40 polymor-
phisms and the risk of clinical and histological disease
progression in 462 subjects followed in the randomized
phase of the trial.
Materials and methods
Eligible Hepatitis C Antiviral Long-term Treatment
against Cirrhosis (HALT-C) Trial subjects had detect-
able serum HCV RNA and bridging hepatic fibrosis (i.e.
Ishak fibrosis score  3) or cirrhosis on a pretreatment
liver biopsy and documented failure to achieve a sus-
tained virological response to a prior course of inter-
feron with or without ribavirin; all subjects had
clinically compensated liver disease at entry (12, 13).
Subjects were retreated with full-dose peginterferon-
a2a, 180 lg/week, and ribavirin, 1.0–1.2 g/day, for
24 weeks in the ‘lead-in phase’ of this study. Subjects
who remained viraemic at treatment week 20 met the
definition of nonresponse and were eligible for random-
ization to maintenance peginterferon-a2a, 90 lg/week,
vs no treatment for 3.5 years; subjects with undetectable
HCV RNA at week 20, as determined by polymerase
chain reaction (PCR) assay (Roche Molecular Systems,
Pleasanton, CA, USA. COBAS Amplicor v 2.0, sensitiv-
ity of 100 IU/ml), were categorized as responders, were
not eligible for randomization, but continued in the
‘responder arm’ of the trial and completed 48 weeks of
full-dose (as tolerated) combination antiviral treatment.
All HALT-C Trial participants entering the lead-in and
randomized phase at 4 of the 10 HALT-C Trial clinical
sites – the University of Michigan, University of Massa-
chusetts/University of Connecticut, Massachusetts Gen-
eral Hospital and the Virginia Commonwealth
University – were eligible for the serum fibrosis marker
ancillary study and had additional serum and DNA col-
lected; samples were frozen immediately at 80°C and
stored at a central repository (SeraCare, Gaithersberg,
MD, USA). This study was approved by local Institu-
tional Review Boards, and all patients provided written
informed consent for both the main trial and this ancil-
lary study, including specific consent for genetic testing.
Fig. 1. Overview of study population. There were 456 patients
with chronic hepatitis C and advanced fibrosis who were retreated
with peginterferon-a2a/ribavirin for 24 weeks during the ‘Lead-in’
phase of the HALT-C Trial included in the current study. Two-hun-
dred and eighty-eight patients who failed to clear HCV RNA at
week 20 entered the randomized phase, whereas 63 patients who
had a virological relapse/breakthrough after 24–48 weeks of pegin-
terferon/ribavirin therapy also entered the randomized phase.
Finally, there were 111 ‘Express’ patients who had received pegin-
terferon/ribavirin therapy and entered the randomized phase. All
the subjects were followed for clinical and histological liver disease
progression through a median follow-up of 3.8 years.
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Laboratory and clinical assessment during the randomized
phase
Routine baseline laboratory values (e.g. serum AST,
ALT, albumin, bilirubin, platelet count) were obtained
at local hospital laboratories. A baseline liver biopsy
obtained within 12 months of enrolment was scored by
consensus among a group of hepatopathologists for the
degree of hepatic fibrosis and inflammation defined by
the Ishak scoring system, and the degree of hepatic stea-
tosis was estimated as grade 0–4 (17, 18). All patients
were seen every 3 months during the randomized phase
for laboratory and clinical assessment. In addition,
annual liver ultrasounds were obtained to screen for
hepatocellular carcinoma (HCC), and serum alpha-foe-
toprotein levels were obtained every 3 months. Clinical
endpoints for this study included an increase in the
Child-Turcotte-Pugh (CPT) score to  7 on two sepa-
rate occasions 3 months apart, variceal bleeding, ascites,
spontaneous bacterial peritonitis, hepatic encephalopa-
thy, HCC or death. For the subgroup of patients with
noncirrhotic fibrosis at baseline, histological progression
was defined as a  2-point increase in the Ishak fibro-
sis score (12).
YKL-40 serum assay
Stored serum samples were tested for YKL-40 levels with
a commercially available ELISA kit (Metra YKL-40, Qui-
del, San Diego, CA, USA) as described previously (Nor-
mal range: 24–125 ug/L) (14).
Testing for YKL-40 promoter polymorphisms
DNA was extracted at SeraCare from frozen whole
blood. Genotyping for the single tag nucleotide poly-
morphism (SNP) rs4950928 of the CHI3L1 promoter
polymorphism accounting for the upstream at 131G
? C point mutation on genomic DNA was performed
with allele-specific real-time PCR at a high-throughput
facility (Celera Diagnostics, Alameda, CA, USA). The
YKL-40 genotypes were classified as CC homozygous for
the major allele, CT heterozygous or TT homozygous
for the minor allele. From prior publications and Hap-
Map data, we expected the distribution of YKL-40 geno-
types in Caucasians and African Americans to be
similar. Therefore, to maximize power, we performed
the analyses in all of the patients grouped together but
also performed all of the analyses in Caucasians alone.
Statistical analyses
Log-transformation of non-normally distributed vari-
ables including serum YKL-40 levels was undertaken
when needed. Continuous variables are presented as
means ± standard deviation; we derived additive linear
models for the number of minor alleles (including a
continuous variable for the number of minor alleles) to
compare values by genotype (e.g. test of trend). To
assess changes in serum YKL-40 values over time, we
used random effects models that were fit in SAS based on
proc mixed that included a random effect of time as well
as the interaction of time with genotype (SAS Institute,
Cary, NC, USA).
To predict the risk of clinical progression in liver dis-
ease by YKL-40 promoter polymorphism, we used Cox
proportional hazards regression, and data were censored
at the patient’s last follow-up visit or at 1400 days (i.e.
3.8 years) after randomization, whichever occurred first.
To assess the relationship between histological progres-
sion and YKL-40 genotype, we relied upon complemen-
tary log-log regression analysis. All analyses were
performed at the Data Coordinating Center (New Eng-
land Research Institutes, Watertown, MA, USA) with
SAS statistical software version 9.2 (SAS Institute).
Results
Lead-in analysis population
The baseline features of the 456 patients enrolled in the
lead-in phase of the Hepatitis C Antiviral Long-term
Treatment against Cirrhosis (HALT-C) Trial who
underwent genetic testing are provided in Table 1.
Overall, 283 (68.0%) patients were CC homozygous at
the major allele, 123 were CT heterozygotes (29.6%)
and 10 (2.4%) were TT homozygotes. The CT and TT
genotypes were in Hardy–Weinberg equilibrium
(P = 0.43) in the overall study population as well as in
the Caucasian subgroup (P = 0.48). In addition, the
17% overall frequency of the T allele in these HALT-C
Trial patients is similar to that reported in other patient
populations (10, 11).
The age, demographic features and baseline labora-
tory markers of liver disease severity were similar in the
three YKL-40 genotype subgroups with the exception of
race/ethnicity, serum ALT and BMI. Furthermore, the
histological severity of liver disease was similar, as was
the proportion with oesophageal varices, in all three
subgroups. As expected, baseline serum YKL-40 levels
were significantly lower in the TT subjects compared
with the CT or CC subgroups (1.96 vs 2.25 vs 2.47,
P < 0.001, trend test). Having shown previously that
lower baseline serum YKL-40 levels were independently
associated with week-20 virologic responses, we also
examined the relationship between YKL-40 genotype
and week-20 virologic response. The likelihood of a
week-20 virologic response was similar for the CC and
CT genotypes but somewhat higher for the TT group,
although the difference did not reach statistical signifi-
cance (Table 1). In addition, baseline serum YKL-40
levels differed according to subgroup with those in the
TT subgroup being lowest (Table 1). Serum YKL-40 lev-
els also decreased significantly by week 24; however, the
magnitude of decline in serum YKL-40 levels did not
differ according to subgroup (Fig. 2A). In addition,
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amongst the 158 patients in the responder arm who
received a full 48-week course of peginterferon and riba-
virin, the likelihood of a week-48 and week-72 virologic
response did not differ by YKL-40 genotype (data not
shown). However, assessment of serial serum YKL-40
levels amongst the 158 lead-in responders demonstrated
a significant decline over time and a difference in levels
according to subgroup, but the magnitude of decline in
serum YKL-40 levels did not differ according to sub-
group (Fig. 2B).
Randomized phase analysis
The mean age of the 462 HALT-C Trial subjects enter-
ing the randomized phase in this study was 49.5 years;
70% were men, 71% were Caucasian and 49% were ran-
domized to receive low-dose peginterferon (Table 2,
Fig. 1). Seven (1.7%) were TT minor allele homozyg-
otes, 119 (28.5%) were CT heterozygotes and 292
(70.0%) were CC major allele homozygotes. The distri-
bution of YKL-40 genotypes was in Hardy–Weinberg
equilibrium overall (P = 0.19) and in the Caucasian-
only subset (P = 0.24). Baseline demographics of the
three groups of patients were similar, with the exception
that all of the TT homozygotes, but not the other sub-
groups, were Caucasian. In addition, laboratory markers
of disease severity as well as baseline histological features
were similar in the three groups except for higher serum
AST and ALT levels in the TT subgroup. Baseline serum
YKL-40 levels, however, were significantly lower in the
TT subgroup compared with the CT and CC subgroups
(2.20 vs 2.34 vs 2.50, P < 0.001, trend test).
Table 1. Baseline features of the lead-in HALT-C Trial patients with YKL-40 promoter polymorphism data
Variable
YKL-40 CC
genotype
YKL-40 CT
genotype
YKL-40 TT
genotype Overall* P-value
Number 283 123 10 456
Age 49.1 (7.1) 49.3 (6.8) 46.9 (5.2) 49.2 (7.1) 0.81
Male (%) 203 (71.7) 86 (69.9) 8 (80.0) 324 (71.1) 0.98
Race
Caucasian (%) 203 (71.7) 103 (83.7) 10 (100.0) 338 (74.1) 0.002†
African American (%) 64 (22.6) 13 (10.6) 0 (0) 93 (20.4)
Other (%) 16 (5.7) 7 (5.7) 0 (0) 25 (5.5)
Duration of infection (years) 26.5 (7.8) 28.2 (7.6) 24.9 (3.8) 26.9 (7.7) 0.21
Lifetime alcohol (drinks) 18 717 (31 674) 17 312 (21 453) 15 234 (15 609) 17 441 (27 778) 0.58
Lifetime smoking (pack-years) 15.8 (17.9) 14.8 (16.4) 16.8 (20.9) 15.2 (17.2) 0.70
Diabetes (%) 76 (26.9) 23 (18.7) 5 (50.0) 117 (25.7) 0.55
Mean BMI (kg/m2) 30.0 (5.8) 28.5 (4.7) 30.0 (4.8) 29.6 (5.5) 0.04
%With oesophageal varices 32 (15.2%) 17 (19.5%) 3 (50.0%) 55 (16.5%) 0.08
%With prior IFN and ribavirin 198 (70.0%) 85 (69.1%) 4 (40.0%) 310 (68.0%) 0.25
Laboratory features
Log10 HCV RNA (IU/ml) 6.44 (0.51) 6.41 (0.65) 6.50 (0.52) 6.44 (0.54) 0.74
% Genotype 1 247 (87.3%) 111 (90.2%) 9 (90.0%) 406 (89.0%) 0.41
AST (IU/ml) 89.7 (66.3) 96.0 (71.8) 116.0 (110.1) 93.2 (70.0) 0.20
ALT (IU/ml) 107.1 (66.4) 124.6 (98.9) 145.1 (132.4) 114.7 (81.1) 0.02
AST/ALT 0.87 (0.29) 0.82 (0.23) 0.82 (0.22) 0.85 (0.27) 0.07
Total bilirubin (mg/dl) 0.77 (0.45) 0.77 (0.41) 0.85 (0.55) 0.77 (0.43) 0.86
INR 1.03 (0.10) 1.03 (0.09) 1.05 (0.11) 1.03 (0.10) 0.87
Albumin (g/L) 3.84 (0.37) 3.90 (0.34) 3.80 (0.39) 3.87 (0.36) 0.36
Platelets9103/mm3 177.5 (69.9) 169.7 (59.0) 151.4 (56.7) 174.2 (65.5) 0.14
Log10 YKL-40 (ug/L) 2.47 (0.43) 2.25 (0.41) 1.96 (0.49) 2.39 (0.44) <0.001
Baseline histology
Mean Ishak Fibrosis score 4.00 (1.26) 3.99 (1.24) 4.40 (0.97) 4.01 (1.25) 0.64
% Ishak 5/6 103 (36.4%) 46 (37.4%) 3 (30.0%) 168 (36.8%) 0.96
Mean HAI 7.47 (2.11) 7.27 (2.11) 7.80 (1.99) 7.43 (2.08) 0.64
Steatosis (% 2) 118 (41.7%) 45 (36.6%) 5 (50.0%) 185 (40.6%) 0.60
Virologic response
N (%) with week-20
virologic response
105 (37.1) 45 (36.6) 7 (70.0) 169 (37.1) 0.33
N (%) with week-48
virologic response‡
88/98 (89.8) 39/42 (92.9) 7/7 (100.0) 145/158 (91.8) 0.85
N (%) with week-72 SVR§ 47/105 (44.8) 26/45 (57.8) 3/7 (42.9) 82/169 (48.5) 0.34
*40 patients missing genotype data. Data presented as mean (SD) or n (%).
†P-value tests whether percent Caucasian differs by genotype.
‡There were 169 with virologic response; 158 had complete week-48 data and of those, 147 had genotype data.
§There were 169 with virologic response for which week-72 SVR was relevant.
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Clinical and histological outcomes
During a mean follow-up of 51 months, a primary clini-
cal outcome developed in 69 (15%) of the 462 random-
ized patients, including Child-Turcotte-Pugh increase
(n = 40), hepatocellular carcinoma (n = 7), ascites
(n = 32), encephalopathy (n = 15), variceal bleeding
(n = 8) and death (n = 24). No significant relationship
emerged, however, between YKL-40 genotype and the
risk of a clinical outcome (Table 3). In addition, analy-
ses conducted in patients stratified by treatment group
during the randomized phase failed to demonstrate an
association of YKL-40 genotype with clinical liver dis-
ease progression. Finally, analysis of the 1050 random-
ized patients also failed to demonstrate a significant
association between YKL-40 genotype and risk of devel-
oping a clinical outcome (see Supporting Information
Table S1). A worsening of hepatic fibrosis, defined as an
increase in the Ishak fibrosis score of  2 points at
month 24 or 48 compared to baseline, was a primary
endpoint in the HALT-C Trial for patients with
noncirrhotic fibrosis. Among the 280 patients with a
pretreatment Ishak fibrosis score of < 5, 209 had
a follow-up biopsy that was adequate for analysis, and,
among these, 191 also had YKL-40 genetic data avail-
able. Among these 191 patients, 90 were randomized to
maintenance peginterferon while 101 were not treated.
During follow-up, 70 (33.5%) patients had worsening
hepatic fibrosis, whereas 139 had stable or unchanged
Ishak fibrosis scores, but the distribution of YKL-40
genotypes was not significantly different in subjects with
and without histological progression (Table 4). In addi-
tion, an analysis of the 935 randomized HALT-C Trial
patients with YKL-40 genetic data available showed,
similarly, no association with clinical outcomes nor with
histological outcomes in 432 subjects with paired biop-
sies (see Table S1). In addition, analyses stratified by
treatment group failed to demonstrate associations with
YKL-40 genotype.
During the randomized phase of the trial, serum
YKL-40 levels remained consistently lower in subjects
with the TT genotype than in subjects with the CT and
CC genotypes (Fig. 3). In fitting a model of serial YKL-
40 levels over time, we found that the YKL-40 genotype,
the baseline serum YKL-40 level and the effect of time
were all significant (all P < 0.001). No interaction was
apparent, however, between YKL-40 genotype and
serum YKL-40 levels over time.
Discussion
Host, environmental and genetic factors are thought to
explain, in part, the highly variable rate of hepatic fibro-
sis and clinical progression of liver disease in patients
with chronic hepatitis C (CHC). Recent studies based on
exploratory genome-wide association methodologies
have led to the identification of a series of genes that may
increase an individual patient’s risk of progressing to
advanced fibrosis and cirrhosis (19, 20). In addition,
hypothesis-driven genetic association studies involving a
limited number of polymorphisms in genes that are
linked biologically to hepatic fibrogenesis have been
reported, but their results have not been validated
consistently in independent cohorts (21, 22). Hepatic
YKL-40 mRNA levels correlated strongly with serum
YKL-40 levels in a prospective study of 87 untreated
patients with CHC that were followed prospectively over
10 years (1). In addition, recent reports demonstrated
that a functional polymorphism in the promoter region
(A)
(B)
Fig. 2. Serum YKL-40 levels and YKL-40 genotype in the lead-in/
responder arm of HALT-C. (A) The baseline serum YKL-40 levels
were significantly lower in patients with the TT genotype compared
with those with the CT and CC genotype (P < 0.001). In addition,
the serum YKL-40 levels significantly decreased by week 24
(P < 0.001) and remained significantly lower in the subjects with
the TT genotype compared with those with the CT and CC geno-
type (P < 0.001). (B) In the 158 subjects with a virological response
during the lead-in phase who received a full 48-week course of
peginterferon and ribavirin, the serum YKL-40 levels significantly
decreased over time (P < 0.001) and remained significantly lower
in the subjects with the TT genotype compared with those with the
CT and CC genotype (P < 0.001).
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of the YKL-40 gene was associated with reduced serum
YKL-40 levels in multiple independent patient popula-
tions and with reduced gene expression in peripheral
blood cells (10, 11, 23). Furthermore, based on both
qualitative and quantitative genetic analyses, Berres et al.
(11) showed that in patients with CHC, histological
fibrosis scores and serum YKL-40 levels were associated
after adjustment for other co-factors with YKL-40
Table 2. Baseline features of the randomized HALT-C Trial patients with YKL-40 promoter polymorphism data
Variable
YKL-40 CC
genotype
YKL-40 CT
genotype
YKL-40 TT
genotype Overall P-value
Number 292 119 7 462*
Age (years) 49.7 (6.9) 49.5 (6.7) 48.6 (5.9) 49.5 (7.0) 0.71
Gender (% male) 201 (68.8) 90 (75.6) 5 (71.4) 325 (70.4) 0.21
Race
Caucasian (%) 199 (68.2) 96 (80.7) 7 (100) 329 (71.2) 0.003†
African American (%) 77 (26.4) 17 (14.3) 0 (0) 110 (23.8)
Other (%) 16 (5.5) 6 (5.0) 0 (0) 23 (5.0)
Duration of infection (years) 27.0 (7.4) 27.8 (7.6) 26.3 (5.7) 27.1 (7.4) 0.51
Lifetime alcohol (drinks) 19 355 (31 039) 19 139 (24 303) 15 537 (10 236) 18 514 (28 054) 0.83
Lifetime smoking (pack-years) (%) 17.0 (18.1) 16.0 (16.6) 18.9 (22.9) 16.5 (17.5) 0.75
Diabetes (%) 81 (27.7) 31 (26.1) 4 (57.1) 129 (27.9) 0.65
Mean BMI 30.2 (5.7) 29.5 (5.2) 29.2 (4.5) 29.9 (5.5) 0.20
%With oesophageal varices 50 (17.7%) 24 (20.9%) 3 (42.9%) 83 (18.6%) 0.17
% Lead-in nonresponders 181 (62.0%) 78 (65.6%) 2 (28.6%) 288 (62.3%) 0.83‡
% Breakthrough/relapsers 40 (13.7%) 14 (11.8%) 4 (57.1%) 63 (13.6%)
% Express 71 (24.3%) 27 (22.7%) 1 (14.3%) 111 (24.0%)
Laboratory features
Log10 HCV RNA (IU/ml) 6.48 (0.48) 6.53 (0.51) 6.52 (0.30) 6.50 (0.47) 0.45
% Genotype 1 270 (92.5%) 114 (96.6%) 6 (85.7%) 433 (93.9%) 0.31
AST (IU/ml) 85.1 (49.0) 94.3 (64.8) 138.3 (141.1) 90.0 (60.2) 0.03
ALT (IU/ml) 100.8 (63.2) 119.2 (95.6) 164.3 (172.2) 108.7 (79.7) 0.01
AST/ALT 0.89 (0.28) 0.84 (0.22) 0.86 (0.18) 0.88 (0.26) 0.16
Total Bilirubin (mg/dl) 0.75 (0.37) 0.75 (0.35) 0.57 (0.25) 0.74 (0.36) 0.59
INR 1.03 (0.10) 1.04 (0.09) 1.10 (0.11) 1.03 (0.10) 0.08
Albumin (g/L) 3.80 (0.38) 3.86 (0.34) 3.64 (0.36) 3.83 (0.37) 0.52
Platelets9103/mm3 177.7 (72.4) 168.0 (56.3) 136.5 (62.8) 174.3 (67.1) 0.10
Log10 YKL-40 (ug/L) 2.50 (0.40) 2.34 (0.39) 2.20 (0.57) 2.45 (0.41) <0.001
Baseline histology
Mean Ishak Fibrosis score 4.05 (1.26) 4.11 (1.23) 4.43 (1.40) 4.08 (1.25) 0.48
% Ishak 5/6 111 (38.0%) 50 (42.0%) 3 (42.9%) 182 (39.4%) 0.45
Mean HAI 7.66 (2.08) 7.44 (1.91) 7.29 (2.29) 7.56 (2.03) 0.28
Steatosis (%  2) 130 (44.5%) 52 (43.7%) 3 (42.9%) 204 (44.2%) 0.87
Randomized phase outcomes
N (%) Peginterferon 148 (50.7) 56 (47.1) 2 (28.6) 228 (49.4) 0.28
N (%) Clinical progression 44 (15.1) 20 (16.8) 2 (28.6) 69 (14.9) 0.42
Duration of follow-up (days) 1220 (431) 1249 (401) 1023 (621) 1228 (429) >0.99
Presented as mean (SD) or n (%). T-test for continuous variables and chi-sq P-values for categorical variables.
*44 missing YKL-40 genotype data.
†P-value tests whether percent Caucasian differs by genotype.
‡P-value tests whether proportion of lead-in nonresponders differs by genotype.
Table 3. Risk of clinical liver disease progression by YKL-40 promoter polymorphism at rs4950928
All patients
(n = 462)
With clinical
progression
(n = 69)
Without clinical
progression
(n = 393)
Hazard ratio
(95% CI)* P-value
Homozygous major (CC) 292 (69.9%) 44 (66.7%) 248 (70.5%) 1 Ref 0.47
Heterozygous (CT) 119 (28.5%) 20 (30.3%) 99 (28.1%) 1.19 (0.75, 1.89)
Homozygous minor (TT) 7 (1.7%) 2 (3.0%) 5 (1.4%)
Missing rs4950928 44 3 41
*HR calculated assuming an additive model and a continuous variable for genotype status.
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promoter polymorphisms. Having obtained extensive
serum YKL-40 data in a large group of well characterized
patients with CHC enrolled in the Hepatitis C Antiviral
Long-term Treatment against Cirrhosis (HALT-C) Trial,
we sought to determine whether significant associations
existed between YKL-40 promoter polymorphisms and
serum YKL-40 levels as well as with baseline liver disease
severity, response to antiviral therapy, and clinical and
histological progression of liver disease (14, 15).
The distribution of YKL-40 promoter polymor-
phisms in the HALT-C Trial patients was similar to that
reported in HapMap general population controls as well
as in another large study of patients with asthma (10).
These data suggest that contrary to the findings of Ber-
res et al. (11), YKL-40 promoter polymorphisms are
not protective against the development of advanced liver
fibrosis. However, other host and environmental co-fac-
tors for fibrosis progression that were present in many
HALT-C Trial patients – e.g. history of heavy alcohol
consumption, increased body mass index and diabetes
mellitus – may have overshadowed the protective effect
of a YKL-40 promoter polymorphism (TT) associated
with lower serum YKL-40 levels. In addition, the limited
number of patients with the favourable genotype (TT)
as well as the selection of patients with advanced fibrosis
for entry into the HALT-C Trial may have precluded
the detection of an association between YKL-40 geno-
type and baseline disease severity. Furthermore, the
presence of advanced liver fibrosis in and of itself may
have reduced the clearance of YKL-40 from the circula-
tion, leading to spuriously high serum levels even in
patients with the TT genotype. In support of these con-
cepts, the study by Berres et al. (11) included patients
with CHC who had a broader distribution of fibrosis
scores, ranging from normal (stage 0) to cirrhosis (stage
6), as compared to the more limited distribution of
fibrosis states in the current study (confined to Ishak
stages 3–6); in addition, none of the patients included in
the study by Berres et al. (11) were reported to have
consumed excessive amounts of alcohol, while many
HALT-C Trial subjects, although abstinent at trial entry,
had a history of high-level lifetime alcohol use. Further-
more, the previously reported association between
serum YKL-40 levels and YKL-40 genotype was
restricted to patients with mild hepatic fibrosis (11),
presumably because advanced hepatic fibrosis can result
in reduced clearance of YKL-40 and other serum fibrosis
markers. A significant association between baseline
serum YKL-40 levels and YKL-40 genotype was
observed in the 456 patients entering the lead-in phase
as well as the 462 randomized HALT-C Trial patients
(Tables 1 and 2). The persistence of low serum YKL-40
levels over time in the lead-in patients with genotype TT
compared with those with genotype TC and CC also
suggests the presence of a strong and persistent associa-
tion between YKL-40 genotype and circulating levels of
YKL-40 (Fig. 2).
In addition to pursuing associations between YKL-40
promoter polymorphisms and liver disease progression,
we explored the potential role of YKL-40 promoter
polymorphisms in predicting the outcomes of antiviral
therapy. Multiple recent reports have demonstrated the
importance of interleukin-28B (IL28B) gene polymor-
phisms in predicting the likelihood of achieving viral
suppression during and after peginterferon and ribavirin
therapy in treatment-naı¨ve patients with CHC (24, 25).
Table 4. Risk of histological fibrosis progression by YKL-40 promoter polymorphism at rs4950928
All patients
(n = 209)
With fibrosis
progression
(n = 70)
Without fibrosis
progression
(n = 139)
Hazard ratio
(95% CI)* P-value
Homozygous major (CC) 138 (72.3%) 49 (75.4%) 89 (70.6%) 1 Ref 0.64
Heterozygous (CT) 50 (26.2%) 14 (21.5%) 36 (28.6%) 0.88 (0.53, 1.48)*
Homozygous minor (TT) 3 (1.6%) 2 (3.1%) 1 (<1%)
Missing rs4950928 18 5 13
*Hazard ratio calculated assuming an additive model to compare the 3 genotype groups.
Fig. 3. Serum YKL-40 levels stratified by YKL-40 genotype during
the randomized phase of the HALT-C Trial. At baseline, the serum
YKL-40 levels were significantly lower in subjects with the TT minor
allele compared with the CT heterozygotes and CC homozygotes
(P < 0.0001). Although the serum YKL-40 levels significantly
increased in each subgroup over time (P < 0.0001), they remained
consistently lower in the CC subgroup compared with others
(P < 0.001).
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In addition, a prior analysis of HALT-C Trial patients
demonstrated that the same IL28B polymorphisms are
associated significantly with the likelihood of achieving
a week-20 virological response as well as an sustained
virological response (SVR) following 48 weeks of
therapy (26). In the current study, we did not find a
significant association of the YKL-40 genetic polymor-
phisms with week-20 (on treatment response), week-48
(end-of-treatment response) or week-72 (SVR) virologi-
cal responses. In addition, when we analysed YKL-40
polymorphisms in the entire cohort of 935 HALT-C
Trial lead-in patients with available genetic data
(n = 675 Caucasian), we did not see an association
between this genetic marker and virological response
(data not shown). Therefore, our prior observations that
baseline serum YKL-40 levels are an independent pre-
dictor of virological response during the lead-in phase
of the HALT-C Trial may reflect the association of lower
serum YKL-40 levels with less severe liver disease, which
is known to influence virological responsiveness
(15, 16). Nonetheless, studies of YKL-40 genotype in
treatment-naı¨ve HCV patients with CHC may be
worthwhile in HCV-infected patients with a broader
distribution of disease severity.
We also explored the relationship between YKL-40
promoter polymorphisms and the risk of clinical and
histological liver disease progression over time in a large
cohort of well characterized and prospectively moni-
tored patients with CHC. In the current HALT-C Trial
subset, however, we observed no significant association
between YKL-40 genotype and the risk of clinical or his-
tological liver disease progression (Tables 3 and 4).
When we also analysed YKL-40 genotype in a larger
cohort of 935 randomized HALT-C Trial patients who
had available genetic data, we also failed to find an asso-
ciation of YKL-40 polymorphisms with clinical and his-
tological disease progression (Table S1). Nonetheless,
serum YKL-40 levels remained significantly lower
throughout follow-up monitoring in subjects with the
TT genotype compared to subjects with the CT and CC
genotypes (Fig. 3). Because we showed previously that
baseline serum YKL-40 levels are associated with the risk
of liver disease progression, our current data suggest
that serial measurements of serum YKL-40 levels, not
YKL-40 gene polymorphisms, may prove to be a useful
prognostic marker in patients with CHC and advanced
fibrosis. Our study findings are consistent with other
analyses of the HALT-C Trial cohort that also failed to
demonstrate a genetic predisposition to clinical or histo-
logical progression of liver disease over time (27, 28).
Absence of an association may have resulted, in part,
from the selection of a cohort of patients with advanced
fibrosis for inclusion in the HALT-C Trial. In support of
this notion, recent reports demonstrate that a panel of
seven genetic polymorphisms, ‘CRS-7’, is associated
with the risk of fibrosis progression in patients with
mild CHC but is less useful in patients with more
advanced fibrosis (29, 30).
In conclusion, our study results failed to support a
reduced frequency of the YKL-40 promoter polymor-
phism associated with reduced serum YKL-40 levels in
our population of patients with CHC and advanced
fibrosis. This observation suggests that the previously
reported association of the YKL-40 promoter polymor-
phism with liver disease severity (11) is most useful in
patients with CHC who lack other risk factors or envi-
ronmental co-factors for advanced fibrosis. Our prior
observation that lower baseline serum YKL-40 levels
were associated with improved responsiveness to
peginterferon and ribavirin was probably secondary to
an association of baseline liver disease severity with
serum YKL-40 levels, rather than to an association with
YKL-40 gene expression per se. Absence of an associa-
tion between YKL-40 promoter polymorphisms and the
risk of clinical and histological liver disease progression
also suggests that this locus may be more important in
the initiation and/or development of early fibrosis than
in the progression of more advanced, established liver
fibrosis.
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